NR1H4 and gastrointestinal disease: Previously findings highlight the potential of targeting FXR pathways as a therapeutic strategy to mitigate gut inflammation and related pathologies between FXR, bile acids, and the gut microbiota particularly in understanding and treating gastrointestinal diseases [40].